News

Bridge Therapeutics announced today that they were selected as one of the Top 100 startups to compete and participate in the 9th Annual Startup of the Year Summit. “The Startup of the Year competition is a great way to showcase our innovative approach to treating opioid addiction and chronic pain,” says Dr. Greg Sullivan, founder and Chief Science Officer at Bridge Therapeutics.

Treatment advocates are hailing those new laws as well as several recent changes to federal regulation designed to reduce the stigma around addiction, close gaps in treatment and expand access to critical medications, including naloxone and buprenorphine, a highly effective intervention for opioid addiction.

In a series of presentations at the 2021 virtual meeting of the North American Neuromodulation Society, Lynn R. Webster, MD, and his colleagues concluded that the novel agent was not associated with significantly decreased respiratory drive and also may have a lower risk for abuse potential than oxycodone.

In a Jan. 26 statement, the American Society of Addiction Medicine, the National Council for Behavioral Health and a handful of other addiction advocacy groups urged Congress to eliminate the training requirement as quickly as possible. “As clinicians and advocates on the frontlines of the addiction and overdose crisis, we call on congressional leaders to…

The Department of Health & Human Services has issued guidance to do away with the so-called X-waiver, a move the agency said will increase the number of providers able to deliver medication-assisted treatment and therefore increase patient access to care. “The medical evidence is clear: access to medication-assisted treatment, including buprenorphine that can be prescribed…

“Companies with limited R&D resources can forgo costly and more risky discovery and development of new chemical entities and instead make incremental innovations to existing drugs. In this manner, companies can use the 505(b)(2) regulatory pathway to repurpose or reposition drugs for new indication,” notes Dr. Babul. A 505(b)(2) NDA may differ from a previously…

Dr. David Fiellin, Director of Yale Program in Addiction Medicine, said, “For individuals who come to an emergency department after an opioid overdose and receive buprenorphine, their one-year mortality rate falls by 40%”. The increased recognition of the benefits of buprenorphine comes at a critical time, the researchers said.  

The pandemic has led to regulatory changes: Treatment can now be entirely virtual, including the first appointment. Medicare now pays providers the same for a video appointment as a conventional one — many insurers and Medicaid programs have followed. Patients can get a month’s prescription for buprenorphine instead of just a week’s. Forty percent of…

Birmingham, AL – April 27, 2020 – Bridge Therapeutics Inc. heard today from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application No.142396 for the Company’s lead product candidate, BT-219 (Bunalz™) is “Open and Safe to Proceed”. There were no additional questions or constraints included in the FDA’s communication. Opening…

Birmingham, AL – March 25, 2020 – Bridge Therapeutics Inc. today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Company’s lead product candidate, BT-219 (Bunalz™). BT-219, or Bunalz™, is an investigational new drug applying Catalent’s Zydis® ODT (orally disintegrating tablet) delivery technology…